⚠ Research and educational use only — not for human consumption. Nothing for sale, no dosing advice. PeptideCompare is non-profit and independent.
Compare free →
Suppliers 🛡 Quality & badges 📖 Encyclopedia 📰 Articles 🧪 Calculator
LONGEVITY TOPICS
⚡ NAD+ Precursors 🔑 Sirtuin Activators 🧹 Senolytics ♻️ Autophagy 🔋 Mitochondrial 🌡️ Hormesis
About FAQ Contact Policy
MONOGRAPH No. 098
SEQUENCE
28 amino acids
MW
3326.8 g/mol
CAS
37221-79-7
EU STATUS
Research only
WADA
Not listed
MIN PURITY
≥98% HPLC
View prices →
🧬 Recovery & Healing

VIP — EU research guide.

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide produced throughout the gut, lungs and CNS. It is a potent vasodilator, immunomodulator and circadian rhythm regulator with broad physiological roles.

Last reviewed:

What is VIP?

VIP binds VPAC1 and VPAC2 receptors (formerly known as VIP1R and VIP2R), which are widely distributed in smooth muscle, immune cells and the CNS. It causes smooth muscle relaxation (vasodilation, bronchodilation), stimulates exocrine secretion, modulates T-cell differentiation toward regulatory phenotypes and entrains circadian clocks in the suprachiasmatic nucleus.

What does the research show?

Preclinical data is extensive: VIP shows anti-inflammatory efficacy in models of rheumatoid arthritis, IBD, sepsis and autoimmune neurodegeneration. A small Phase 2 trial in pulmonary arterial hypertension showed functional improvements with inhaled VIP. Research in SARS-CoV-2 lung pathology and long-COVID immune dysregulation has reinvigorated interest.

EU legal status

VIP has no approved drug status in the EU or US (the PAH inhaler trial did not reach approval). Available from EU research vendors for laboratory mechanistic research only.

No approved therapeutic use. Phase 2 data in limited indications only. Short half-life (~2 min) makes therapeutic application complex. Not for human use. This is a research compound, not a medication.
✓ PeptideCompare lists VIP from EU research vendors. VIP is highly sensitive to degradation — verify lyophilisation quality and cold-chain handling.

Molecular information

Molecular formula
C147H237N43O43S
Molecular weight
3326.8 g/mol
CAS number
37221-79-7

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

VIP across EU suppliers

COA-verified EU vendors · Updated monthly

Frequently asked questions

What is VIP?

VIP (vasoactive intestinal peptide) binds VPAC1 and VPAC2 receptors, widely distributed in smooth muscle, immune cells and the CNS. It relaxes smooth muscle, stimulates exocrine secretion, modulates T-cells toward regulatory phenotypes and entrains circadian clocks.

What does the research show?

Preclinical data are extensive, showing anti-inflammatory efficacy in models of rheumatoid arthritis, IBD, sepsis and autoimmune neurodegeneration, and a small Phase 2 trial in pulmonary arterial hypertension showed functional improvements with inhaled VIP.

Why has interest in VIP grown recently?

Research into SARS-CoV-2 lung pathology and long-COVID immune dysregulation has reinvigorated interest in VIP.

What does VIP do in the body?

It relaxes smooth muscle (vasodilation and bronchodilation), stimulates exocrine secretion, shifts T-cell differentiation toward regulatory phenotypes and helps entrain circadian rhythm in the suprachiasmatic nucleus.

Is VIP legal in the EU?

It has no approved drug status and is sold as a research compound for laboratory use only.

Is VIP banned in sport?

It is not currently on the WADA prohibited list.

Related guides

PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
What does COA Verified mean? Most tested supplier? Is this legal here?
Navigation assistant · no medical advice